Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Blopress Remains No. 1 for 7th Term in a Row: Domestic Drug Sales Ranking
January 17, 2011
- Mizuho Securities Lists Halaven, KW-0761 as Promising Anticancer Agents
January 17, 2011
- Pharma Industry Must Drive Nation's Economic Growth: Mr Matsuda
January 17, 2011
- Bayer, Regeneron Report Positive Results from 2 Studies on VEGF Trap-Eye
January 17, 2011
- Mr Matsutani Calls For Closer Cooperation with Makers to Settle Prices Quickly
January 17, 2011
- SymBio Starts PII Trial of Transdermal Antiemetic in Japan
January 17, 2011
- Morishita Jintan Merges Jintan Tech
January 17, 2011
- Prospects for Simultaneous Global Development: 3
January 17, 2011
- Hospira Japan to Begin Development of Biosimilars in Japan
January 10, 2011
- Korosho Obliged to Make a Sensitive Decision on Actos Generics
January 10, 2011
- NIBIO Identifies Structure of TNF-TNFR2 Complex
January 10, 2011
- Wakunaga Signs an MTA with A-CUBE for Therapeutic MABs
January 10, 2011
- Velcade Approved for Naive MM Patients
January 10, 2011
- DSP, Chugai to Jointly Develop MDS Vaccine
January 10, 2011
- Kyorin Refuses Sawai Further Explanations
January 10, 2011
- Lunabell Approved for Functional Dysmenorrhea
January 10, 2011
- Takeda Signs Anti-Obesity Drug Discovery Partnership Agreement
January 10, 2011
- ViiV Reduces Operation Costs Utilizing GSK's Business Resources
January 10, 2011
- Daiichi Sankyo's Sevikar HCT Approved in Germany
January 10, 2011
- Fulvestrant Better Controls Breast Cancer than Anastrozole: AZ
January 10, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…